相关实验视频
Updated: May 27, 2025

05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
4.4K
在乳腺癌中研究化疗诱导的心脏功能障碍
Sai Harini Chandrasekaran1, Pugazhendi Inban2, Reeju Maharjan3
1Department of Respiratory Medicine, Vijaya Hospitals, Chennai, India.
Journal of chemotherapy (Florence, Italy)
|February 21, 2025
概括
乳腺癌的化疗可以导致心脏问题,如左心室功能障碍 (LVD). 较年轻的左侧瘤和ER阳性状态的年轻患者面临更高的风险,特别是在治疗trastuzumab时. 早期监测和量身定制的策略对于管理心脏风险至关重要.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 癌症治疗可以提高生存率,但会带来心脏毒性等风险.
- 化疗引起的心脏功能障碍是乳腺癌患者日益关注的问题.
研究的目的:
- 在新诊断的乳腺癌患者中评估化疗相关的心脏功能障碍.
- 确定风险因素和易患左心室功能障碍 (LVD) 的患者子组.
主要方法:
- 对接受化疗的97名新诊断乳腺癌患者进行前性研究.
- 心脏功能评估,包括左心室功能障碍 (LVD) 的评估.
- 对患者人口统计,瘤特征和治疗方案的分析.
主要成果:
- 13.4%的患者出现左心室功能障碍 (LVD).
- 在年轻患者,左侧瘤和雌激素受体 (ER) 阳性状态中,LVD发病率较高.
- 特拉斯图祖马布的使用与38.5%的LVD发病率有关;累积化疗剂量没有显著的相关性.
结论:
- 化疗在乳腺癌患者中存在严重的心脏功能障碍的风险.
- ER阳性和trastuzumab是LVD的关键危险因素.
- 持续的心脏监测和个性化治疗对于减轻心脏毒性至关重要.
相关概念视频
Heart Failure Drugs: Inotropic Agents
499
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
499
Imbalances in Cardiac Output
1.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
371
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
371
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K

